NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Rituximab in combination with corticosteroids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
 Roche Products (rituximab) Patient/carer groups Afiya Trust Arthritis Care Black Health Agency British Kidney Patient Association British Lung Foundation Equalities National Council Independent Age Kidney Alliance Kidney Research UK Lauren Currie Twilight Foundation Lupus UK Muslim Council of Britain Muslim Health Network National Kidney Federation National Rheumatoid Arthritis Society (NRAS) 	 Allied Health Professionals Federation Association of Renal Industries Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium
South Asian Health FoundationSpecialised Healthcare AllianceVasculitis UK	 Welsh Kidney Patients Association Welsh Urological Society Comparator Manufacturers
 Professional groups Association of Renal Technologists Association for Respiratory Technology and Physiology Association of Respiratory Nurse Specialists British Association for Paediatric Nephrology British Association for Services to the Elderly British Association of Urological Nurses British Association for Urological Surgeons British Geriatrics Society British Health Professionals in 	 Actavis UK (azathioprine, mycophenolate) Arrow Generics (azathioprine) Aspen Medical Europe (azathioprine) Baxter Healthcare (cyclophosphamide) Dr Reddy's Laboratories (UK) (mycophenolate) Hameln Pharmaceutical (methotrexate) Hospira UK (methotrexate) Medac UK (methotrexate) Mercury Pharma Group (methotrexate) Mylan UK(azathioprine, mycophenolate) Novartis Pharmaceuticals (mycophenolate) Orion Pharma (UK) (methotrexate) Pfizer (cyclophosphamide, methotrexate) Roche Products (mycophenolate)

National Institute for Health and Clinical Excellence Matrix for the technology appraisal of rituximab in combination with corticosteroids for treating antineutrophil cytoplasmic antibody-associated vasculitis Issue date: January 2013

Rheumatology

- British Renal Society
- British Society for Rheumatology
- British Society for Paediatric and Adolescent Rheumatology
- British Thoracic Society
- Primary Care Respiratory Society UK
- Primary Care Rheumatology Society
- Renal Association
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicines
- Society for DGH Nephrologists
- UK Renal Pharmacy Group
- United Kingdom Clinical Pharmacy Association
- Urology Foundation (formerly British Urological Foundation)

Others

- Department of Health
- Bournemouth & Poole, and Dorset PCT Cluster
- Cwm Taf Health Board
- Welsh Government

- Sandoz (azathioprine, methotrexate)
- Sinclair Pharmaceuticals (azathioprine)
- Teva UK (azathioprine,methotrexate, mycophenolate)
- Zentiva UK (mycophenolate)

Relevant research groups

- Arthritis Research UK
- British Association for Lung Research
- Cochrane Acute Respiratory Infections Group
- Cochrane Renal Group
- MRC Clinical Trials Unit
- National Institute for Health Research
- Research Institute for the Care of Older People
- Vasculitis Rare Disease Working Group of the UK and Ireland- UKVas

Evidence Review Group

- School of Health and Related Research Sheffield (ScHARR)
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

National Clinical Guidelines Centre

Associated Public Health Groups

None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.